Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.
about
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesMeasuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumabTargeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluationIn vivo targeting of HER2-positive tumor using 2-helix affibody molecules.Inorganic nanoparticle-based contrast agents for molecular imagingModular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry.A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.Molecular targeting of CEACAM6 using antibody probes of different sizes.The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals.A fluorescent imaging method for analyzing the biodistribution of therapeutic monoclonal antibodies that can distinguish intact antibodies from their breakdown productsPET imaging with ⁸⁹Zr: from radiochemistry to the clinicPositron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments.In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.Protein-based tumor molecular imaging probes.Long-term multimodal imaging of tumor draining sentinel lymph nodes using mesoporous silica-based nanoprobesMonitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors[(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice.Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.Molecular Imaging of Ovarian CancerEfficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticalsThe rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.The challenges of integrating molecular imaging into the optimization of cancer therapy.Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.Molecular imaging in ovarian cancer.An update on the role of PET/CT and PET/MRI in ovarian cancer.Development of multi-functional chelators based on sarcophagine cages.
P2860
Q28266067-D2F5A28D-B2CF-4CDD-952D-9D30B8439ECCQ33527397-386B67BC-308B-42BA-BB91-39E7F484385FQ33661325-20B04126-4B0F-40E3-B459-AC0409F64E26Q33765280-3A12F501-9E93-45F4-838A-1DABFA630EF4Q34102029-2EF0DC8E-F9C9-4240-8421-98F7110754DDQ34231627-79469DCC-053C-47C5-8AE0-470A0C5ECAD9Q34644628-0DD0E744-4F74-480F-A15B-C106AB849BBEQ35394166-4E292BB9-A8EB-4CE6-BA24-018AF51D2B95Q35650526-C22E6958-9D38-47D9-B863-2AD2F27D8879Q36044493-69D42B58-047E-4C10-AACD-F610909BD62EQ36052972-E7B15C37-C7C8-457D-8D09-C10E4FE04108Q36215502-36A46FE6-76C3-4677-8EC7-CB7C3CA2975FQ36454584-73F6B2C4-943A-47E0-AE4A-4EA335C44A49Q36557471-0472F1A2-9BE5-4E6C-8AEA-94584571F6E1Q36647014-A39A54A5-8298-4CC8-9BA1-B1B826B7B444Q36742911-6A7F6490-008C-4F33-A7F9-A90F9606D265Q37136682-B0333CD2-E54E-479F-8FED-DB445D0E7DC7Q37141350-9B9D30D7-673D-4632-BD72-205418E8E9DBQ37148669-9B70FAB4-7B52-455B-9C11-460CA45BAF79Q37268891-62641A84-C5F5-46B6-9ED2-9057124A468AQ37273125-CA63F822-01DC-47B8-8680-693B939DE2F5Q37305724-FC2E8B6D-BB77-40D9-9D27-7AB3CAEAEECDQ37722948-EA668576-E337-46BD-A4DA-6950249CCE32Q37869905-0055BE8E-8D80-4960-800D-8EF961119307Q37871875-D03D578E-87B4-4C6E-BBBA-2402BDC73D22Q38003390-2B6CCC88-B537-4B51-A240-782D93A7CA86Q38824319-07AD712E-465A-4B74-A1F2-825284FD1F9AQ39127714-E6A7E7D2-1939-415B-912E-ADB40D7F116EQ46321334-CA4730D4-2B5B-48B8-BF82-92FE3D1762F4
P2860
Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@ast
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@en
type
label
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@ast
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@en
prefLabel
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@ast
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@en
P2860
P1476
Monitoring therapeutic respons ...... with (64)Cu-DOTA-trastuzumab.
@en
P2093
P2860
P2888
P304
P356
10.1007/S00259-009-1158-1
P577
2009-05-14T00:00:00Z